LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: Prognostic impact of the post-treatment T cell composition and spatial organization in soft tissue sarcoma patients treated with neoadjuvant hyperthermic radio(chemo)therapy.

    Rupp, Luise / Resag, Antonia / Potkrajcic, Vlatko / Warm, Verena / Wehner, Rebekka / Jöhrens, Korinna / Bösmüller, Hans / Eckert, Franziska / Schmitz, Marc

    Frontiers in immunology

    2023  Volume 14, Page(s) 1185197

    Abstract: Soft tissue sarcomas (STS) form a heterogeneous group of tumors sharing a mesenchymal origin. Despite good local control of the disease, the occurrence of distant metastases often limits survival of STS patients with localized, high-risk tumors of the ... ...

    Abstract Soft tissue sarcomas (STS) form a heterogeneous group of tumors sharing a mesenchymal origin. Despite good local control of the disease, the occurrence of distant metastases often limits survival of STS patients with localized, high-risk tumors of the extremities. Accumulating evidence suggests a central role for the tumor immune microenvironment in determining the clinical outcome and response to therapy. Thus, it has been reported that STS patients with a high immune signature and especially presence of B cells and tertiary lymphoid structures display improved overall survival and response to checkpoint inhibitor treatment. Here, we explored the effect of curative multimodal therapy on the T cell landscape of STS using multiplex immunohistochemistry. We analyzed the phenotype, frequency, and spatial distribution of STS-infiltrating CD8
    MeSH term(s) Humans ; Neoadjuvant Therapy ; CD8-Positive T-Lymphocytes ; Programmed Cell Death 1 Receptor ; Ki-67 Antigen ; Hyperthermia, Induced ; Sarcoma/pathology ; Soft Tissue Neoplasms/pathology ; Tumor Microenvironment
    Chemical Substances Programmed Cell Death 1 Receptor ; Ki-67 Antigen
    Language English
    Publishing date 2023-05-16
    Publishing country Switzerland
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2606827-8
    ISSN 1664-3224 ; 1664-3224
    ISSN (online) 1664-3224
    ISSN 1664-3224
    DOI 10.3389/fimmu.2023.1185197
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Tumor-targeted therapy with BRAF-inhibitor recruits activated dendritic cells to promote tumor immunity in melanoma.

    Hornsteiner, Florian / Vierthaler, Janine / Strandt, Helen / Resag, Antonia / Fu, Zhe / Ausserhofer, Markus / Tripp, Christoph H / Dieckmann, Sophie / Kanduth, Markus / Farrand, Kathryn / Bregar, Sarah / Nemati, Niloofar / Hermann-Kleiter, Natascha / Seretis, Athanasios / Morla, Sudhir / Mullins, David / Finotello, Francesca / Trajanoski, Zlatko / Wollmann, Guido /
    Ronchese, Franca / Schmitz, Marc / Hermans, Ian F / Stoitzner, Patrizia

    Journal for immunotherapy of cancer

    2024  Volume 12, Issue 4

    Abstract: Background: Tumor-targeted therapy causes impressive tumor regression, but the emergence of resistance limits long-term survival benefits in patients. Little information is available on the role of the myeloid cell network, especially dendritic cells ( ... ...

    Abstract Background: Tumor-targeted therapy causes impressive tumor regression, but the emergence of resistance limits long-term survival benefits in patients. Little information is available on the role of the myeloid cell network, especially dendritic cells (DC) during tumor-targeted therapy.
    Methods: Here, we investigated therapy-mediated immunological alterations in the tumor microenvironment (TME) and tumor-draining lymph nodes (LN) in the D4M.3A preclinical melanoma mouse model (harboring the V-Raf murine sarcoma viral oncogene homolog B (BRAF)
    Results: Our findings reveal that BRAF-inhibitor therapy increased tumor immunogenicity, reflected by an upregulation of genes associated with immune activation. The T cell-inflamed TME contained higher numbers of activated cDC1 and cDC2 but also inflammatory CCR2-expressing monocytes. At the same time, tumor-targeted therapy enhanced the frequency of migratory, activated DC subsets in tumor-draining LN. Even more, we identified a cDC2 population expressing the Fc gamma receptor I (FcγRI)/CD64 in tumors and LN that displayed high levels of CD40 and CCR7 indicating involvement in T cell-mediated tumor immunity. The importance of cDC2 is underlined by just a partial loss of therapy response in a cDC1-deficient mouse model. Both CD4
    Conclusion: Our results give novel insights into the remodeling of the myeloid landscape by tumor-targeted therapy. We demonstrate that the transient immunogenic tumor milieu contains more activated DC. This knowledge has important implications for the development of future combinatorial therapies.
    MeSH term(s) Humans ; Animals ; Mice ; Melanoma/metabolism ; CD8-Positive T-Lymphocytes ; Proto-Oncogene Proteins B-raf/genetics ; Dendritic Cells ; Antigens, Neoplasm ; Tumor Microenvironment
    Chemical Substances Proto-Oncogene Proteins B-raf (EC 2.7.11.1) ; Antigens, Neoplasm ; BRAF protein, human (EC 2.7.11.1)
    Language English
    Publishing date 2024-04-17
    Publishing country England
    Document type Journal Article
    ZDB-ID 2719863-7
    ISSN 2051-1426 ; 2051-1426
    ISSN (online) 2051-1426
    ISSN 2051-1426
    DOI 10.1136/jitc-2023-008606
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: The Immune Contexture of Liposarcoma and Its Clinical Implications.

    Resag, Antonia / Toffanin, Giulia / Benešová, Iva / Müller, Luise / Potkrajcic, Vlatko / Ozaniak, Andrej / Lischke, Robert / Bartunkova, Jirina / Rosato, Antonio / Jöhrens, Korinna / Eckert, Franziska / Strizova, Zuzana / Schmitz, Marc

    Cancers

    2022  Volume 14, Issue 19

    Abstract: Liposarcomas (LPS) are the most frequent malignancies in the soft tissue sarcoma family and consist of five distinctive histological subtypes, termed well-differentiated LPS, dedifferentiated LPS (DDLPS), myxoid LPS (MLPS), pleomorphic LPS, and myxoid ... ...

    Abstract Liposarcomas (LPS) are the most frequent malignancies in the soft tissue sarcoma family and consist of five distinctive histological subtypes, termed well-differentiated LPS, dedifferentiated LPS (DDLPS), myxoid LPS (MLPS), pleomorphic LPS, and myxoid pleomorphic LPS. They display variations in genetic alterations, clinical behavior, and prognostic course. While accumulating evidence implicates a crucial role of the tumor immune contexture in shaping the response to anticancer treatments, the immunological landscape of LPS is highly variable across different subtypes. Thus, DDLPS is characterized by a higher abundance of infiltrating T cells, yet the opposite was reported for MLPS. Interestingly, a recent study indicated that the frequency of pre-existing T cells in soft tissue sarcomas has a predictive value for immune checkpoint inhibitor (CPI) therapy. Additionally, B cells and tertiary lymphoid structures were identified as potential biomarkers for the clinical outcome of LPS patients and response to CPI therapy. Furthermore, it was demonstrated that macrophages, predominantly of M2 polarization, are frequently associated with poor prognosis. An improved understanding of the complex LPS immune contexture enables the design and refinement of novel immunotherapeutic approaches. Here, we summarize recent studies focusing on the clinicopathological, genetic, and immunological determinants of LPS.
    Language English
    Publishing date 2022-09-21
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers14194578
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top